Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceGrazia Arpino, Rachel Schiff|Endocrine Reviews|2008Cited by 545
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic FunctionSuleiman Massarweh, Rachel Schiff, C. Kent Osborne et al.|Cancer Research|2008Cited by 494
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft ModelsXiaomei Zhang, Michael T. Lewis, Sofie Claerhout et al.|Cancer Research|2013Cited by 485
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven TumorigenesisJessica D. Kessler, Thomas F. Westbrook, Kristopher T. Kahle et al.|Science|2011Cited by 440
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers - role of estrogen receptor and HER2 reactivationYen-Chao Wang, Rachel Schiff|Breast Cancer Research|2011Cited by 283